Genetic Disease Licensing Life Science Marketing 
XTalks
DECEMBER 29, 2022
The life sciences and healthcare are among the biggest industries globally, and their significance was particularly highlighted during the past couple of years by the COVID-19 pandemic. Given the hyperfocus on the life sciences thanks to COVID, consumers appear to be more autonomous and vocal about their medical demands and choices.
pharmaphorum
DECEMBER 8, 2021
If approved, the drug will be sold by Neuren Pharma, which licensed North American rights to the drug in 2018 and is also developing another drug for Rett blarcamesine, in collaboration with Anavex Life Sciences. The post Acadia closer to bringing first Rett syndrome drug to market appeared first on.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 17, 2021
But that number doesn’t quite reflect the company’s likely market valuation , which is expected to be between $9 billion and $12 billion. Based in Seattle, Washington, Sana focuses on in vivo and ex vivo cell engineering platforms to develop therapies for cancer, diabetes, cardiovascular disease, CNS disorders, and genetic diseases.
pharmaphorum
OCTOBER 16, 2020
These might be licensed drugs that could hold potential for a patent extension, or drugs which failed efficacy trials for an intended indication. Findacure is a charity that works directly with rare disease patient groups to help them grow and professionalise. The post Rare diseases, repurposing and the role of AI appeared first on.
The Pharma Data
DECEMBER 8, 2020
December is bringing frost in the North and plenty of cold hard cash for these life sciences companies. . European venture capital firm Forbion rounded up $545 million for its fifth life sciences fund. Cornering the untapped Chinese CNS market, SciNeuro launched with $100 million in their pocket.
XTalks
APRIL 24, 2023
Rare diseases can often be progressive, chronic and fatal. Approximately 72 percent of rare diseases are genetic, and around 70 percent of rare genetic diseases emerge in childhood. Sadly, one-third of children with rare diseases die before their first birthday. How Can Study Protocols Be More Effective?
XTalks
DECEMBER 13, 2023
Moreover, it has submitted global marketing authorization applications for mRNA-1345, a vaccine designed to prevent RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD), supported by favorable data from a predefined interim analysis. vaccine, mRNA-1273.815. million, compared to $1.1
Expert insights. Personalized for you.
52 
Let's personalize your content